Dexpramipexole

The (R)-(+) enantiomer of PRAMIPEXOLE. Dexpramipexole has lower affinity for DOPAMINE RECEPTORS than pramipexole.

Also Known As:

KNS 760704; KNS-760704; KNS760704; Pramipexol, (R)-isomer; SND 919CL2x; SND-919CL2x; SND919CL2x; (6R)-4,5,6,7-Tetrahydro-N6-Propyl-2,6-Benzothiazole-Diamine; (R)-2-Amino-6-Propylamino-4,5,6,7-Tetrahydrobenzothiazole; (R)-Pramipexole; R-(+)-Pramipexole

Networked: 33 relevant articles (2 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        Dexpramipexole: 33
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - Dexpramipexole: 33

Experts

1.	Bozik, Michael E: 8 articles (01/2019 - 01/2008)
2.	Buonvicino, Daniela: 5 articles (06/2021 - 01/2018)
3.	Chiarugi, Alberto: 5 articles (06/2021 - 01/2018)
4.	Muzzi, Mirko: 4 articles (01/2020 - 01/2018)
5.	Coppi, Elisabetta: 3 articles (06/2021 - 01/2018)
6.	Ranieri, Giuseppe: 3 articles (06/2021 - 01/2020)
7.	Dworetzky, Steven I: 3 articles (01/2019 - 01/2017)
8.	Hebrank, Gregory T: 3 articles (01/2019 - 01/2017)
9.	Sullivan, Mary: 3 articles (01/2019 - 11/2011)
10.	Dong, Yingwen: 3 articles (12/2014 - 01/2013)

Related Diseases

1.	Eosinophilia 11/01/2023 - "We sought to evaluate the safety and efficacy of dexpramipexole in lowering blood and airway eosinophilia in subjects with eosinophilic asthma. " 01/01/2019 - "Dexpramipexole and tyrosine kinase inhibitors have been shown to reduce eosinophil numbers in patients with hypereosinophilia. " 01/01/2019 - "Because the oral investigational drug dexpramipexole serendipitously decreased blood eosinophils in amyotrophic lateral sclerosis studies, we assessed its safety, eosinophil-lowering activity, and preliminary clinical efficacy in patients with CRSwNP and eosinophilia. "
2.	Asthma (Bronchial Asthma) 11/01/2023 - "Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial." 11/01/2023 - "Additional larger clinical trials are needed to understand the clinical efficacy of dexpramipexole in asthma." 11/01/2023 - "Refashioning dexpramipexole: A new horizon in eosinophilic asthma?" 11/01/2023 - "Dexpramipexole, an oral eosinophil-lowering drug, has not previously been studied in asthma. " 11/01/2023 - "We sought to evaluate the safety and efficacy of dexpramipexole in lowering blood and airway eosinophilia in subjects with eosinophilic asthma. "
3.	Sepsis-Associated Encephalopathy 01/01/2023 - "Dexpramipexole ameliorates cognitive deficits in sepsis-associated encephalopathy through suppressing mitochondria-mediated pyroptosis and apoptosis." 01/01/2023 - "This study was aimed at evaluating the effects of dexpramipexole (DPX) - a mitochondrial protectant that sustains mitochondrial function and energy production - on cognitive function in a mouse model of sepsis-associated encephalopathy (SAE) induced by peripheral administration of lipopolysaccharide (LPS) and examining the potential mechanisms. "
4.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/01/2018 - "Dexpramipexole (KNS-760704), an orally bioavailable synthetic aminobenzothiazole, showed an excellent safety profile and was coincidentally noted to significantly decrease absolute eosinophil counts (AECs) in a phase 3 trial for amyotrophic lateral sclerosis. " 11/15/2014 - "Dexpramipexole (DEX) was being investigated in clinical studies for the treatment of amyotrophic lateral sclerosis (ALS). " 11/01/2013 - "In a phase 2 study, dexpramipexole (25-150 mg twice daily) was well tolerated for up to 9 months and showed a significant benefit at the high dose in a combined assessment of function and mortality in patients with amyotrophic lateral sclerosis. " 11/01/2013 - "Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial." 01/01/2013 - "Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics."
5.	Polyps 01/01/2019 - "Sixteen subjects with CRSwNP, absolute eosinophil count (AEC) ≥ 0.300 × 109 /L, and polyp tissue eosinophils were evaluable for efficacy in a 6-month open-label, multi-center study of dexpramipexole 150 mg twice daily. " 11/28/2023 - "Almost complete eosinophil depletion with dexpramipexole had no impact on polyp size reduction or clinical improvement. " 01/01/2019 - "Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size."

Related Drugs and Biologics

1.	Pramipexole (Mirapex)
2.	Investigational Drugs
3.	Lipopolysaccharides
4.	Adenosine Triphosphate (ATP)
5.	benzothiazole
6.	Steroids
7.	Dexpramipexole
8.	Riluzole
9.	Dopamine Agonists (Dopamine Agonist)
10.	Reactive Oxygen Species (Oxygen Radicals)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia